课题基金 / 基金详情

CD4+ and CD8+ T cell dependent immune mechanisms of rhinovirus-mediated asthma ex

CD4+ and CD8+ T cell dependent immune mechanisms of rhinovirus-mediated asthma ex
鼻病毒介导的哮喘的 CD4 和 CD8 T 细胞依赖性免疫机制
批准号:
7975934
负责人:
LARRY C BORISH
金额:
$30.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-06-01 至 2012-05-31

项目摘要

项目成果

LARRY C BORISH的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):与哮喘相关的最大发病率是发生严重的、可能危及生命的恶化。鼻病毒(RV)占儿童哮喘恶化的60%-70%。尽管每当细胞病变炎症反应叠加在哮喘肺上时,就会预测到哮喘的恶化,但这并不是观察到的情况-只有轮状病毒感染与哮喘加重一致地相关。RV相关的恶化与2型细胞因子信号(IL-4、-5和-13)的增加有关,一种解释是这些细胞因子是由RV特异性T细胞本身产生的,要么是CD4+辅助T细胞(Th2样),要么是CD8+细胞毒性T淋巴细胞(Tc2样)。对病毒感染作出反应的T淋巴细胞会产生对宿主有害的炎症反应。病情恶化也与抗炎细胞因子IL-10的表达减少有关。IL-10可能控制与旺盛的T细胞反应相关的附带损害。我们认为,感染过程中IL-10的来源很可能是效应器T细胞本身。目的/假设:我们建议将重点放在RV特异性效应/记忆T细胞产生2型细胞因子和IL-10,以预测自然RV感染后哮喘恶化的发展。我们假设,在RV感染期间病情恶化的儿童和青少年的RV特异性记忆T细胞释放更高水平的2型细胞因子和/或更低水平的IL-10。我们将识别感染RV的哮喘儿童,并验证我们识别循环中RV特异性的CD4+辅助细胞和CD8+细胞毒性T淋巴细胞的能力。具体目标1将招募哮喘儿童和青少年,我们将对他们进行前瞻性的RV感染评估,并量化对他们哮喘的影响。轮状病毒感染将在定期就诊时和在上呼吸道感染提示时通过鼻分泌物的定量聚合酶链式反应来诊断。轮状病毒感染的影响将主要通过乙酰甲胆碱敏感性的变化来评估。我们的初步研究表明,在秋季轮状病毒大流行期间,50%的儿童将证明有感染的证据,其中~一半的感染将与哮喘恶化有关,定义为乙酰甲胆碱敏感度增加2倍。具体目标#2将研究RV特异性T细胞协调哮喘恶化的概念。我们将评估急性RV感染后循环中RV特异性T记忆细胞的患病率和细胞因子谱。我们将鉴定RV特异性记忆T细胞,并定义它们产生1型(干扰素-3)和2型细胞因子(IL-4、-5和-13)。我们将同时定义IL-10的细胞产生。我们认为RV特异性辅助性T细胞(CD4+)和细胞毒性效应/记忆性T细胞(CD8+)中的高2型/低IL-10细胞因子谱将预测哮喘的恶化。 公共卫生相关性:产生“普通感冒”(鼻病毒)的病毒是大多数儿童和青少年哮喘恶化的原因,因此也是大多数住院和哮喘死亡的原因。造成这种病毒这一独特特征的机制是一个谜。尽管只有一小部分哮喘患者面临严重恶化、紧急护理转诊、住院或死亡的风险,因为我们无法识别有风险的个人,但目前的指南鼓励对除最轻微的哮喘患者外的所有患者进行积极的日常治疗。确定鼻病毒与免疫系统相互作用导致哮喘加重的机制,对于确定哪些儿童有哮喘加重的风险,以及最有可能从具体的预防和治疗干预中受益的儿童至关重要。
英文摘要
DESCRIPTION (provided by applicant): The greatest morbidity associated with asthma is the occurrence of severe, potentially life- threatening exacerbations. Rhinovirus (RV) accounts for ~60-70% of childhood asthma exacerbations. Although an exacerbation would be predicted whenever a cytopathic inflammatory response is superimposed upon the asthmatic lung, this is not what is observed - and only RV infections are consistently associated with asthma exacerbations. RV-associated exacerbation are linked to the presence of an increased type 2 cytokine signature (IL-4, -5, and -13) and one explanation is that these cytokines are being produced by the RV-specific T cells themselves, either CD4+ helper (Th2-like) or CD8+ cytotoxic (Tc2-like) T lymphocytes. T lymphocytes responding to a viral infection produce inflammatory responses that can be harmful to the host. Exacerbations are also linked to the presence of diminished expression of the anti-inflammatory cytokine IL-10. IL-10 may to control the collateral damage associated with an exuberant T cell response. The source of this IL-10 during infection, we believe, is likely the effector T cells themselves. Objective/Hypothesis: We propose to focus on the production of type 2 cytokines and IL-10 by RV-specific effector/memory T-cells that predict the development of an asthma exacerbation following natural RV infection. We hypothesize that RV-specific memory T cells from children and adolescents who develop an exacerbation during RV infection release higher levels of type 2 cytokines and/or lower levels of IL-10. We will identify children with asthma who become infected with RV and validate our ability to identify circulating RV-specific CD4+ helper and CD8+ cytotoxic T effector lymphocytes. Specific aim #1 will enroll asthmatic children and adolescents who we will prospectively evaluate for RV infections and quantify the impact on their asthma. RV infection will be diagnosed by quantitative PCR of nasal secretions at regular clinic visits and when prompted by upper respiratory infections. Impact of RV infection will be evaluated primarily as change in methacholine sensitivity. Our preliminary studies demonstrate that during the fall RV pandemic >50% of children will demonstrate evidence for infection and ~half of those infections will be associated with an asthma exacerbation defined as a >2-fold increase in methacholine sensitivity. Specific aim #2 will examine the concept that RV-specific T cells orchestrate asthma exacerbations. We will assess the prevalence and cytokine profile of circulating RV-specific T memory cells after acute RV infections. We will identify RV-specific memory T cells and will define their production of type 1 (IFN-3) and type 2 cytokines (IL-4, -5, and -13). We will simultaneously define cellular production of IL-10. We propose that a high type 2/ low IL-10 cytokine profile within RV-specific helper (CD4+) and cytotoxic (CD8+) effector/memory T cells will predict asthma exacerbations. PUBLIC HEALTH RELEVANCE: The virus producing the "common cold" (rhinovirus) is responsible for most childhood and adolescent asthma exacerbations and, as such, most hospitalizations and deaths from asthma. The mechanism responsible for this unique feature of this virus is an enigma. Even though only a small subset of asthmatics is at risk for severe exacerbations, urgent care referral, hospitalization, or death, because of our inability to identify at risk individuals, current guidelines encourage aggressive daily treatment of all but the mildest asthmatics. Identifying the mechanism through which rhinovirus interacts with the immune system to produce an asthma exacerbation is central to identifying children who are at risk for asthma exacerbations and are most likely to benefit from specific interventions for prevention and treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protracted clinical and inflammatory response to rhinovirus challenge in human asthmatics
  • 批准号:
    10540527
  • 项目类别:
  • 资助金额:
    $32.3万
  • 财政年份:
    2022
  • 负责人:
    LARRY C BORISH
  • 依托单位:
Clinical response to rhinovirus challenge in human asthmatics
  • 批准号:
    9893778
  • 项目类别:
  • 资助金额:
    $69.98万
  • 财政年份:
    2016
  • 负责人:
    LARRY C BORISH
  • 依托单位:
Clinical response to rhinovirus challenge in human asthmatics
  • 批准号:
    9081696
  • 项目类别:
  • 资助金额:
    $69.98万
  • 财政年份:
    2016
  • 负责人:
    LARRY C BORISH
  • 依托单位:
Clinical immune response to rhinovirus challenge in human asthmatics
  • 批准号:
    9075457
  • 项目类别:
  • 资助金额:
    $38.63万
  • 财政年份:
    2015
  • 负责人:
    LARRY C BORISH
  • 依托单位:
海外基金